Alps Advisors Inc. grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 17.2% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 23,740 shares of the biopharmaceutical company’s stock after acquiring an additional 3,481 shares during the period. Alps Advisors Inc.’s holdings in Gilead Sciences were worth $1,680,000 as of its most recent filing with the SEC.

Other institutional investors also recently added to or reduced their stakes in the company. Seizert Capital Partners LLC raised its stake in shares of Gilead Sciences by 4.6% in the 1st quarter. Seizert Capital Partners LLC now owns 632,574 shares of the biopharmaceutical company’s stock valued at $42,964,000 after acquiring an additional 27,547 shares during the period. Linscomb & Williams Inc. raised its stake in shares of Gilead Sciences by 3.0% in the 1st quarter. Linscomb & Williams Inc. now owns 5,275 shares of the biopharmaceutical company’s stock valued at $358,000 after acquiring an additional 154 shares during the period. Investment Centers of America Inc. raised its stake in shares of Gilead Sciences by 7.2% in the 1st quarter. Investment Centers of America Inc. now owns 29,064 shares of the biopharmaceutical company’s stock valued at $1,979,000 after acquiring an additional 1,958 shares during the period. HealthInvest Partners AB raised its stake in shares of Gilead Sciences by 3.5% in the 1st quarter. HealthInvest Partners AB now owns 117,000 shares of the biopharmaceutical company’s stock valued at $7,947,000 after acquiring an additional 4,000 shares during the period. Finally, Capital Asset Advisory Services LLC purchased a new stake in shares of Gilead Sciences in the 2nd quarter valued at approximately $875,000. 73.97% of the stock is currently owned by institutional investors and hedge funds.

A number of research firms have recently issued reports on GILD. Jefferies Group LLC reissued a “hold” rating and issued a $80.00 price target on shares of Gilead Sciences in a research note on Tuesday, July 11th. BMO Capital Markets reaffirmed an “outperform” rating and set a $82.00 target price (up from $72.00) on shares of Gilead Sciences in a research note on Thursday, July 27th. Robert W. Baird reaffirmed an “outperform” rating and set a $87.00 target price on shares of Gilead Sciences in a research note on Thursday, July 13th. J P Morgan Chase & Co reaffirmed an “overweight” rating and set a $82.00 target price on shares of Gilead Sciences in a research note on Tuesday, July 4th. Finally, BidaskClub raised shares of Gilead Sciences from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 22nd. Twelve investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the stock. Gilead Sciences currently has a consensus rating of “Buy” and an average price target of $85.80.

Gilead Sciences, Inc. (NASDAQ:GILD) opened at 80.24 on Wednesday. The firm’s 50-day moving average is $82.48 and its 200-day moving average is $72.25. The stock has a market cap of $104.79 billion, a P/E ratio of 8.72 and a beta of 1.14. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The company had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. During the same quarter in the previous year, the company posted $3.08 earnings per share. The company’s revenue for the quarter was down 8.2% compared to the same quarter last year. On average, equities analysts forecast that Gilead Sciences, Inc. will post $8.73 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Friday, September 15th were issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.59%. The ex-dividend date of this dividend was Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is 22.58%.

In other news, EVP Gregg H. Alton sold 15,000 shares of the business’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $75.88, for a total transaction of $1,138,200.00. Following the completion of the transaction, the executive vice president now owns 106,113 shares of the company’s stock, valued at $8,051,854.44. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Gregg H. Alton sold 40,000 shares of the business’s stock in a transaction on Friday, July 21st. The shares were sold at an average price of $74.00, for a total transaction of $2,960,000.00. Following the transaction, the executive vice president now directly owns 137,488 shares of the company’s stock, valued at approximately $10,174,112. The disclosure for this sale can be found here. In the last three months, insiders have sold 486,819 shares of company stock valued at $39,298,919. Corporate insiders own 1.30% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Gilead Sciences, Inc. (GILD) Shares Bought by Alps Advisors Inc.” was first published by Daily Political and is owned by of Daily Political. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/10/18/gilead-sciences-inc-gild-shares-bought-by-alps-advisors-inc.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.